Hvor er det et vildt regnskab fra Novo Nordisk! Jeg glaeder mig til at laese regnskabet i loebet af weekenden. Bemaerk, at der p.t. for Saxenda® er en lillebitte fejl i grafen, fordi Novo tidligere blandede salg for Saxenda® og Wegovy® sammen i en paere-vaelling. Men Saxenda® salg oeges fra DKKm 1551 til 1998 (+6%) til trods for lancering af Wegovy® (DKKm 1404).
Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=112994
Operating profit increased by 28% in Danish kroner and by 18% at constant exchange rates (CER) to DKK 19.1 billion.
Sales in International Operations increased by 18% in Danish kroner (13% at CER), and sales in North America Operations increased by 33% in Danish kroner (24% at CER).
Sales within Diabetes and Obesity care increased by 27% in Danish kroner to DKK 36.7 billion (20% at CER), mainly driven by GLP-1 diabetes sales growth of 54% in Danish kroner (45% at CER). Rare disease sales increased by 8% measured in Danish kroner (3% at CER).
Obesity care sales grew 119% in Danish Kroner (107% at CER) driven by Wegovy® sales of DKK 1.4 billion. The contract manufacturer filling syringes for Wegovy® has reinitiated commercial production and Novo Nordisk expects to make all Wegovy® dose strengths available in the US during the second half of 2022.
Within R&D, Novo Nordisk in April 2022 successfully completed the first phase 3a trial with insulin icodec, a long-acting once-weekly insulin. In February 2022, the phase 3 trial with concizumab in people with haemophilia A and B with inhibitors was successfully completed.
For the 2022 outlook, sales growth is now expected to be 10-14% at CER and operating profit growth is now expected to be 9-13% at CER. Sales and operating profit growth reported in Danish kroner are now expected to be 7 and 11 percentage points higher than at CER, respectively. The ongoing share repurchase programme is expanded by DKK 2 billion to DKK 24 billion
Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=112994
Operating profit increased by 28% in Danish kroner and by 18% at constant exchange rates (CER) to DKK 19.1 billion.
Sales in International Operations increased by 18% in Danish kroner (13% at CER), and sales in North America Operations increased by 33% in Danish kroner (24% at CER).
Sales within Diabetes and Obesity care increased by 27% in Danish kroner to DKK 36.7 billion (20% at CER), mainly driven by GLP-1 diabetes sales growth of 54% in Danish kroner (45% at CER). Rare disease sales increased by 8% measured in Danish kroner (3% at CER).
Obesity care sales grew 119% in Danish Kroner (107% at CER) driven by Wegovy® sales of DKK 1.4 billion. The contract manufacturer filling syringes for Wegovy® has reinitiated commercial production and Novo Nordisk expects to make all Wegovy® dose strengths available in the US during the second half of 2022.
Within R&D, Novo Nordisk in April 2022 successfully completed the first phase 3a trial with insulin icodec, a long-acting once-weekly insulin. In February 2022, the phase 3 trial with concizumab in people with haemophilia A and B with inhibitors was successfully completed.
For the 2022 outlook, sales growth is now expected to be 10-14% at CER and operating profit growth is now expected to be 9-13% at CER. Sales and operating profit growth reported in Danish kroner are now expected to be 7 and 11 percentage points higher than at CER, respectively. The ongoing share repurchase programme is expanded by DKK 2 billion to DKK 24 billion
29/4 2022 11:15 Stockwatch1 7
103164 Novo Nordisk shares rose 6% after a surprise early report showing much better than expected first-quarter earnings and a big boost to full-year guidance.
Outlook FY revenue growth 10-14%, up from 6-10% previously, while Outlook FY EBIT growth 9-13%, up from 4-8% previously
• Q1 sales DKK 42,031 million vs. estimate DKK 38,575 million, with Wegovy at DKK 1.4 billion despite supply issues
• We did not expect a guidance raise already in the first quarter, analysts at Carnegie said
• The guidance raise and the magnitude send a strong signal this early in the year: Carnegie
Outlook FY revenue growth 10-14%, up from 6-10% previously, while Outlook FY EBIT growth 9-13%, up from 4-8% previously
• Q1 sales DKK 42,031 million vs. estimate DKK 38,575 million, with Wegovy at DKK 1.4 billion despite supply issues
• We did not expect a guidance raise already in the first quarter, analysts at Carnegie said
• The guidance raise and the magnitude send a strong signal this early in the year: Carnegie
29/4 2022 14:06 DjengisCash 7103170 Vækst var ventet, men alligevel vildt. Den stærke dollar hjælper til, når væksten opgøres i danske kroner. Ved uændret valuta er væksten alligevel 18 procent.
Og så har Wegovy knap nok lagt fra land endnu. Det der virkelig trækker op er væksten i GLP1 på 54 procent, virkelig overraskende. Havde selv regnet med højst 40 procent på segmentet.
Markedet reager dog behersket, vil jeg sige.
Og så har Wegovy knap nok lagt fra land endnu. Det der virkelig trækker op er væksten i GLP1 på 54 procent, virkelig overraskende. Havde selv regnet med højst 40 procent på segmentet.
Markedet reager dog behersket, vil jeg sige.
Mon ikke analytikerne kommer på banen i næste uge med købsanbefalinger og opskrivning af kursmål? Den slags plejer at hjælpe på kursen.
Der har været flere nye kursmål på Novo. De siger 900kr
29/4 2022 19:09 Helge Larsen/PI-redaktør 1103181 Er de kommet efter regnskabet i dag? Det syntes jeg ikke at have set.
30/4 2022 11:26 SofC I 0103187 Den synes allerede dyr, men det er der vel en grund til. Nu har jeg ikke nærlæst den, men denne her er fra 29-April-2022:
https://seekingalpha.com/article/4505430-novo-nordisk-stock-overvalued-pharma-should-be-rotated
Det ændret nok ikke på at danskerne ikke kan få armene ned.
https://seekingalpha.com/article/4505430-novo-nordisk-stock-overvalued-pharma-should-be-rotated
Det ændret nok ikke på at danskerne ikke kan få armene ned.
1/5 2022 10:58 DjengisCash 2103198 Denne meddelse fra den største konkurrent skal nok lægge en dæmper på euforien.
https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or
https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or
1/5 2022 15:28 tommycarstensen 4103201 DjengisCash Tusind tak for link. Jeg havde ikke set den endnu.
1) Baade ja og nej; se kommentar fra Fruergaard nedenfor. Victoza® blev heller ikke slaaet til plukfisk af Trulicity® i sin tid i det voksende og stadigt voksende GLP1-diabetes-marked.
2) Og saa er Tirzepatid ikke et oralt laegemiddel, og Novo har oral semaglutid mod fedme i fase 3, og mon ikke det bliver godkendt ligesom diabetes-pendanten Rybelsus®?
3) De 22,5% vaegttab bliver kun opnaaet ved hoejeste dosis paa 15mg.
Men naar alt det er sagt, saa synes jeg ogsaa, at kursen paa Novo er alt for hoej.
Jeg har forresten ikke set artiklen med resultaterne fra fedme-studiet SURMOUNT-1, men vedhaeftet en figur fra diabetes-studiet SURPASS-2 publiceret i NEJM:
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
Klik paa figurerne for at goere dem stoerre.
2021-11-03
After strong quarter, Novo Nordisk urges more competitive US obesity market
https://www.reuters.com/business/cop/novo-nordisk-q3-earnings-lifted-by-demand-new-obesity-drug-2021-11-03/
But he said more competition would make more doctors recognise obesity as a disease that can be treated with drugs.
"We would welcome more competitors to actually help establish that market," Jorgensen said.
1) Baade ja og nej; se kommentar fra Fruergaard nedenfor. Victoza® blev heller ikke slaaet til plukfisk af Trulicity® i sin tid i det voksende og stadigt voksende GLP1-diabetes-marked.
2) Og saa er Tirzepatid ikke et oralt laegemiddel, og Novo har oral semaglutid mod fedme i fase 3, og mon ikke det bliver godkendt ligesom diabetes-pendanten Rybelsus®?
3) De 22,5% vaegttab bliver kun opnaaet ved hoejeste dosis paa 15mg.
Men naar alt det er sagt, saa synes jeg ogsaa, at kursen paa Novo er alt for hoej.
Jeg har forresten ikke set artiklen med resultaterne fra fedme-studiet SURMOUNT-1, men vedhaeftet en figur fra diabetes-studiet SURPASS-2 publiceret i NEJM:
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
Klik paa figurerne for at goere dem stoerre.
2021-11-03
After strong quarter, Novo Nordisk urges more competitive US obesity market
https://www.reuters.com/business/cop/novo-nordisk-q3-earnings-lifted-by-demand-new-obesity-drug-2021-11-03/
But he said more competition would make more doctors recognise obesity as a disease that can be treated with drugs.
"We would welcome more competitors to actually help establish that market," Jorgensen said.
1/5 2022 16:05 Helge Larsen/PI-redaktør 2103202 Meddelelsen kom torsdag. Kursen faldt efterfølgende.
https://www.proinvestor.com/investornyt/815223/novo-rival-viser-lovende-data-med-wegovy-konkurrent
https://www.proinvestor.com/investornyt/815223/novo-rival-viser-lovende-data-med-wegovy-konkurrent
De kom før opjusteringen. Der kommer nye mål i næste uge. Der skal jo justeres op på de gamle kursmål.
30/4 2022 16:05 Helge Larsen/PI-redaktør 0103193 Netop..Dem fra de seneste uger har vi sendt rundt på ProInvestor. Forstod dit skriv som om det var nye efter regnskabet i går.
29/4 2022 15:12 tommycarstensen 6103172 DjengisCash Jeg tror den beherskede reaktion trods den flotte vaekst og det flotte regnskab skal ses i lyset af de meget hoeje multipler.
29/4 2022 17:47 DjengisCash 5103179 Tommy, ja den er dyrt prissat på multipler og en pæn del af væksten har nok været indregnet allerede. I næste uge kommer der sikkert en række justeringer af kursmål, der driver prisen yderligere mod nord.
Apropros prissætning, så skrev jeg vist for nyligt, at Mærsk skulle koste 256.000 kr., hvis prissætningen skulle matche Novo på P/E.
God weekend
Apropros prissætning, så skrev jeg vist for nyligt, at Mærsk skulle koste 256.000 kr., hvis prissætningen skulle matche Novo på P/E.
God weekend
Jeg synes det er lidt skræmmende, kursen kan vil ikke vokse ud i det uendelige? Hvor er grænsen?
Udbytte procenten og indtjeningen i forhold til kursen er vel ikke videre imponerende?
Ja, jeg spørger bare.
(jeg har Novo)
Udbytte procenten og indtjeningen i forhold til kursen er vel ikke videre imponerende?
Ja, jeg spørger bare.
(jeg har Novo)
1/5 2022 14:54 bikube 0103200 Der er ingen øvre grænse. Når kursen kommer højt nok op, så laver de et split 1-10, og starter forfra. Det plejer Novo at gøre. Det var vist Kuno, der sagde, at Novo kan jo ikke blive ved med, at vokse 15% om året. Nu er vi tæt på, at gøre det igen.
30/4 2022 12:03 nicklasabs 3103188 "Ingen over og ingen ved siden af Novo Nordisk", som Per Hansen ville have sagt det 
30/4 2022 21:33 tommycarstensen 4103195 Jeg fik skrevet, at salget af Saxenda® blev oeget til trods for lancering af Wegovy® og fik antydet, at Wegovy® ikke har kannibaliseret Saxenda®.
Da jeg skrev det, var "financial workbook" for kvartalet ikke blevet uploadet hertil endnu:
https://www.novonordisk.com/investors/financial-results.html
Det er ikke i USA, at Saxenda® vokser, hvilket den ene af de to vedhaeftede figurer viser. Den anden figur viser, at Wegovy® allerede er stoerre end Saxenda® i USA; hhv DKKm 1404 og 704 i foerste kvartal.
Klik paa billederne for at goere dem stoerre.
Da jeg skrev det, var "financial workbook" for kvartalet ikke blevet uploadet hertil endnu:
https://www.novonordisk.com/investors/financial-results.html
Det er ikke i USA, at Saxenda® vokser, hvilket den ene af de to vedhaeftede figurer viser. Den anden figur viser, at Wegovy® allerede er stoerre end Saxenda® i USA; hhv DKKm 1404 og 704 i foerste kvartal.
Klik paa billederne for at goere dem stoerre.
16/5 2022 20:53 tommycarstensen 2103509 FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes
https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and
https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and
